SLURP2: A Potential Drug Target and Biomarker (G432355)

Target Name: SLURP2

NCBI ID: G432355

SLURP2

SLURP2: A Potential Drug Target and Biomarker

SLURP2, or Secreted Ly-6/uPAR domain-containing protein 2, is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to investigate, and its potential as a drug or biomarker has led to a growing interest in the field of molecular medicine.

SLURP2 is a protein that is expressed in a variety of tissues throughout the body, including the brain, spleen, heart, and lymphatic system. Its primary function is to regulate the interactions between cells and tissues, specifically between immune cells and cancer cells. This protein plays a crucial role in the regulation of immune surveillance and tissue homeostasis, and its dysfunction has been implicated in a number of diseases.

One of the key features of SLURP2 is its ability to interact with multiple cell types and tissues. This makes it a potential drug target, as drugs that can specifically interact with SLURP2 may have therapeutic benefits for a variety of diseases. For example, studies have shown that SLURP2 is involved in the regulation of immune cell function, and that its dysfunction in this pathway has been implicated in the development of autoimmune disorders. Additionally, SLURP2 has also been shown to play a role in cancer progression and the regulation of cell division, making it an attractive target for anti-cancer drugs.

Another potential application of SLURP2 as a drug target is its role in neurodegenerative diseases. SLURP2 has been shown to be involved in the regulation of axon growth and differentiation, as well as neuroprotection against oxidative stress. Its dysfunction in these processes has been implicated in the development and progression of neurodegenerative diseases, making it a potential target for therapies that aim to slow or reverse the progression of these conditions.

In addition to its potential as a drug target, SLURP2 has also been identified as a potential biomarker for a variety of diseases. Its expression has been shown to be associated with a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Additionally, studies have shown that SLURP2 has the potential to serve as a biomarker for drug responses, as its levels can be affected by certain medications and therapeutic approaches.

Overall, SLURP2 is a protein that has the potential to be a drug target and biomarker for a variety of diseases. Its unique structure and function make it an attractive target for researchers to investigate, and its potential as a therapeutic agent is a promising area of research. Further studies are needed to fully understand the role of SLURP2 in disease and to develop effective therapies that can benefit from its properties.

Protein Name: Secreted LY6/PLAUR Domain Containing 2

Functions: Binds and may modulate the functional properties of nicotinic and muscarinic acetylcholine receptors. May regulate keratinocytes proliferation, differentiation and apoptosis. In vitro moderately inhibits ACh-evoked currents of alpha-3:beta-2-containing nAChRs and strongly these of alpha-4:beta-2-containing nAChRs, modulates alpha-7-containing nAChRs, and inhibits nicotine-induced signaling probably implicating alpha-3:beta-4-containing nAChRs. Proposed to act on alpha-3:beta-2 and alpha-7 nAChRs in an orthosteric, and on mAChRs, such as CHRM1 and CHRM3, in an allosteric manner

The "SLURP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLURP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets